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Abstract
The recent development of whole genome association studies has lead to the robust identification of several loci involved
in different common human diseases. Interestingly, some of the strongest signals of association observed in these studies
arise from non-coding regions located in very large introns or far away from any annotated genes, raising the possibility that
these regions are involved in the etiology of the disease through some unidentified regulatory mechanisms. These findings
highlight the importance of better understanding the mechanisms leading to inter-individual differences in gene expression
in humans. Most of the existing approaches developed to identify common regulatory polymorphisms are based on
linkage/association mapping of gene expression to genotypes. However, these methods have some limitations, notably
their cost and the requirement of extensive genotyping information from all the individuals studied which limits their
applications to a specific cohort or tissue. Here we describe a robust and high-throughput method to directly measure
differences in allelic expression for a large number of genes using the Illumina Allele-Specific Expression BeadArray platform
and quantitative sequencing of RT-PCR products. We show that this approach allows reliable identification of differences in
the relative expression of the two alleles larger than 1.5-fold (i.e., deviations of the allelic ratio larger than 60:40) and offers
several advantages over the mapping of total gene expression, particularly for studying humans or outbred populations.
Our analysis of more than 80 individuals for 2,968 SNPs located in 1,380 genes confirms that differential allelic expression is
a widespread phenomenon affecting the expression of 20% of human genes and shows that our method successfully
captures expression differences resulting from both genetic and epigenetic cis-acting mechanisms.
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Introduction
Understanding the genetic causes of phenotypic variation in
humans still remains a major challenge for human genetics. In
hundreds of cases, a single DNA sequence polymorphism affecting
a protein coding sequence has been linked to a clear simple
Mendelian phenotype (see e.g. [1]) and, for a much smaller but
increasing number of cases, to more complex phenotypes [2–4].
Recent developments in high-density genotyping technologies
have led to the completion of several whole genome association
studies that test hundreds of thousands of markers for a specific
disease. While earlier studies essentially focused on variants in
coding sequences and regions immediately surrounding candidate
genes, whole genome scans interrogate, in an unbiased way, most
of the human genome including large regions of non-coding DNA
that had not been studied previously. Interestingly, some of the
strongest signals observed in these association studies are located in
non-coding regions, either in large introns (e.g. [5–7]) or far away
from any annotated loci (e.g. [8] and references therein). The
mechanisms connecting these polymorphisms to the etiology of the
diseases are still unclear but regulation of gene expression remains
an obvious candidate. It is thus becoming particularly important to
have a powerful and reliable method to easily test the influence of
DNA polymorphisms on gene expression. One of the approaches
commonly used to identify regulatory polymorphisms is to look for
statistical associations between variation in gene expression and
individual genotypes [9,10]. This method offers the advantage of
simultaneously analyzing thousands of genes using gene expression
arrays and has yielded fascinating results in yeast [11,12] and
mouse [13–16]. Its application in humans [17–24] suffers from
relatively low statistical power due to potential inter-individual
differences in a large number of causal variants involved in the
regulation of a specific gene [25], their modest effects and the
burden of the multiple testing correction necessary to take into
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addition, since this approach requires extensive genotype infor-
mation for all individuals, it is costly to apply to new samples. An
alternative approach is to compare the relative expression of the
two alleles in one individual: the effect of a polymorphism affecting
in cis the regulation of a particular transcript can be detected by
measuring the relative expression of the two alleles in heterozygous
individuals using a transcribed SNP as a marker [26–32]. Several
studies have used this approach in humans but have been
criticized for their low throughput or the apparent high variability.
Here we describe a novel array-based method that allows high-
throughput assessment of differential allelic expression. We used a
modified version of the Illumina GoldenGate genotyping platform,
the Allele-Specific Expression (ASE) assay, to assess the extent of
differential allelic expression for over 1300 genes in more than 80
human lymphoblastoid cell lines (LCLs). Our analyses include 352
genes located in ENCODE regions and chromosome 21 that have
been previously screened for cis-regulatory polymorphisms using
total gene expression [19]. This allows us to directly compare the
advantages and drawbacks of the two approaches in terms of
range, sensitivity and robustness. We specifically address the issue
of experimental noise and reproducibility of the findings and show
that biology, not experimental variability, is responsible for the
patterns observed. We discuss the relevance of our results for the
identification of the molecular mechanisms regulating gene
expression, as well as their implications for future genetic studies.
Results
Assessment of Differential Allelic Expression Using
Illumina ASE Assay
We first assessed the extent of differential allelic expression at
1,432 exonic SNPs using 81 individual LCLs with the Illumina
ASE technology (Figure 1 and Table S1 for the composition of the
Illumina ASE Cancer Panel). This technology uses primer
extension assays with fluorescence-labeled allele-specific primers
to measure the proportion of each allele separately at the genomic
and transcriptomic levels (Figure 2). Five hundred and twelve
SNPs (in 345 genes) displayed an expression level significantly
higher than background in at least three heterozygous individuals
and were further investigated (see Materials and Methods for
details). The extent of differential allelic expression at each SNP
was obtained by comparing the relative amount of each allele in
RNA to the ratio observed in DNA.
As a first effort to determine if the assay could reliably be used to
assess differential expression we generated spike mixes using
varying proportions of total RNA extracts from two individuals.
For 20 exonic SNPs located in expressed transcript, the two
individuals are homozygous for the different alleles (i.e. respec-
tively AA and BB), while for 192 SNPs one individual is
Author Summary
We describe a new methodology to identify individual
differences in the expression of the two copies of one
gene. This is achieved by comparing the mRNA level of the
two alleles using a heterozygous polymorphism in the
transcript as marker. We show that this approach allows an
exhaustive survey of cis-acting regulation in the genome;
we can identify allelic expression differences due to
epigenetic mechanisms of gene regulation (e.g. imprinting
or X-inactivation) as well as differences due to the
presence of polymorphisms in regulatory elements. The
direct comparison of the expression of both alleles nullifies
possible trans-acting regulatory effects (that influence
equally both alleles) and thus complements the findings
from gene expression association studies. Our approach
can be easily applied to any cohort of interest for a wide
range of studies. It notably allows following up association
signals and testing whether a gene sitting on a particular
haplotype is over- or under-expressed, or can be used for
screening cancer tissues for aberrant gene expression due
to newly arisen mutations or alteration of the methylation
patterns.
Figure 1. Experiment design and results obtained for the two panels used in the study. The Overall column corresponds to the
combination of the two panels. The detailed composition of each panel is presented on Supplemental Table S1.
doi:10.1371/journal.pgen.1000006.g001
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AB and BB). Since the expression of each gene may differ between
the two individuals, one does not expect to observe an exact
translation of the proportions of total RNA mixed to the ‘‘allelic’’
expression level. However, the allelic expression differences
estimated for the different spike mixes should be the proportional
to each other. For all homozygous/homozygous mixes (20 out of
20 SNPs) and 83% of the heterozygous/homozygous mixes (159
out of 192), we observed a significant linear correlation (p,0.05)
between the proportion of mixed total RNAs and the ‘‘allele-
specific expression’’ estimated by the assay (Figure 3 and
Figure S1).
We then tried to assess the threshold above which differential
allelic expression would be genuine: even if the two alleles are
equally expressed in one individual, we expect the ratio of allelic
expression measured at a given marker to deviate stochastically
from 50:50 due to experimental variability. In order to
differentiate technical noise from biological signal (i.e. the
differences in allelic expression due to differential cis-acting
regulation), we evaluated the extent of experimental variability
in the assay by comparing independent estimates of allelic
imbalance for duplicates of individual RNA. We used duplicated
measurements from 81 individuals at all SNPs expressed to
determine a robust estimation of the experimental variability (N=
31,503 duplicates). After averaging duplicate differences for each
SNP over all individuals, we observed than less than 3% of the
SNPs show a population average variability greater than 10% (see
Materials and Methods for more details and Figure S2). This level
of experimental variability corresponds to a ratio of allelic
expression of 60:40 (i.e. 1.5-fold difference). Thus, population-
average allelic expression ratio at any SNP lower than 60:40 can
be explained by experimental noise, while a SNP displaying a
population-average differential allelic expression greater than this
threshold most likely reflects a biological process affecting cis-
Figure 2. Overview of the Illumina Allele-Specific Expression assay. Genomic DNA and total RNA are separately converted into biotinylated
DNA and amplified using fluorescence-labeled universal primers following extension and ligation of allele-specific assay oligo-nucleotides. PCR
products are captured by locus-specific beads and the fluorescence of each dye (i.e. allele) at each locus is measured by quantitative fluorescence
imaging (see Materials and Methods for details).
doi:10.1371/journal.pgen.1000006.g002
Figure 3. Result of the spike mixes experiment for four genes.
The graph shows the logarithm of the dye ratio (y-axis) for four mixes of
total RNA extract (x-axis) of NA12155 (at 0 on the x-axis) and NA07000
(at 1 on the x-axis). The original RNA extracts mixed and the four mixes
for FRK (rs580396) are shown in blue, for GNAS (rs7121) in pink, for
ITPR3 (rs2229634) in yellow and for RAD52 (rs1051672) in green.
doi:10.1371/journal.pgen.1000006.g003
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loci with common allelic expression differences and we thus
focused on population-average differential allelic expression: the
average over all heterozygous individuals of the extent of allelic
expression differences, regardless of which allele is over expressed
(this is addressed later). The identification of a single individual
with dramatic allelic expression difference is also possible using the
same approach (but a different detection cut-off) but is beyond the
scope of this paper. Among the 345 genes expressed in this first
panel (512 SNPs), 72 (87 SNPs) displayed an average level of allelic
imbalance larger than this 40:60 cut-off and were thus considered
to display significant differences in allelic expression (Figure 4).
These analyses rely on the observation of the three genotypes in
the population (i.e. AA, AB and BB). To also include SNPs with a
lower minor allele frequency for each it was not possible to observe
homozygotes for the minor allele in our small sample, we designed
a second analysis method using solely the heterozygous individ-
uals. If the alleles are differentially regulated we expect to observe
in some cases a very large variance in the ratio of the two alleles in
the population. We used this approach to determine SNPs for
which the heterozygous individuals harbor a variance of the allelic
ration higher than expected using a Maximum expectation
algorithm (see Materials and Methods for details). This approach
does not allow us to quantity the overall extent of differential allelic
expression but identifies 8 genes with differential allelic expression
that were not identified by the previous method.
When one considers the estimates of allelic expression obtained
using different SNPs in a same transcript showing significant
differences in allele expression (i.e. with a population-average ratio
greater than 60:40), we note that 36 out of 44 correlations between
individuals estimates are significant (for an average r
2 of 0.83).
Individuals showing a large allelic expression difference at one
SNP display similar patterns at all heterozygous positions of the
transcript (an example is shown on Figure 5). This observation
supports our findings that the experimental variability is low in the
Illumina ASE assay and that this assay allows quantitative
assessment of differential allelic expression. Consequently, the
population-average estimates of allelic imbalance obtained with
different markers in the same transcript tend to be similar (Table
S2) but can vary since different individuals will be included in the
average (depending on whether they are heterozygotes at this
marker).
Validation of Allelic Imbalance Estimates Using
Quantitative Sequencing
To further assess the validity of our results, we randomly
selected 25 genes tested on the Illumina ASE platform and used
quantitative sequencing of RT-PCR products [33] to measure
allelic imbalance for the same SNP in the same individuals (Figure
Figure 4. Population-average estimates of allelic expression at 416 SNPs from the first panel. Each blue cross stands for one SNP and is
displayed on the left y-axis based on the average allelic ratio observed using all heterozygous individuals for this SNP. The SNPs are ranked on the x-
axis from 1 (SNP with the highest average allelic imbalance) to 416 (lowest average allelic imbalance). Green dots stand for SNPs in imprinted genes,
pink dots for SNPs in X-linked genes. The red line represents our significance threshold based on the estimation of experimental variability and
corresponds to an average allelic ratio of 40:60. The red crosses are the 25 SNPs also analyzed using quantitative sequencing of RT-PCR products and
are displayed on the right y-axis according to the strength of the correlation (Pearson’s r
2) between the estimates of both methods (i.e., 1 indicates
complete correlation between both estimations, 0 no correlation). Non significant correlations (p.0.05) are indicated with r
2=0.
doi:10.1371/journal.pgen.1000006.g004
Figure 5. Estimates of allelic expression using two SNPs
located in the IL1A gene. Each blue cross displays one individual
heterozygous at two SNPs in IL1A. The x-axis represents the estimate of
allelic imbalance using rs1304037, the y-axis the allelic imbalance
measured using rs17561. The two axes cross at 50:50 corresponding to
an equal expression of both alleles, the allelic ratio 100:0 corresponds to
complete transcriptional silencing of one allele, 0:100 to the silencing of
the other allele.
doi:10.1371/journal.pgen.1000006.g005
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significant allelic imbalance and 17 genes for which the level of
differential allelic expression did not reach our significance
threshold. We analyzed the same 81 individual LCLs using
RNA from the same extract as for the Illumina assay. Overall, we
observed a strong correlation between the estimates of allelic
imbalance obtained for each individual using the two methods for
the genes with a ratio of allelic expression larger than our 40:60
cut-off (r
2.0.8 for 6 out of 8 genes, see Figure 6A as a example).
The correlations were not statistically significant for the genes for
which the average difference in allelic imbalance did not reach our
significance threshold (16 out of 17 genes, Figure 6B): minor
deviations observed in the allelic ratio for these genes likely
correspond to random variations and are therefore not expected to
be reproducible. The strength of the correlation (measured by
Pearson’s r
2) for all 25 genes is shown on Figure 4. One SNP in
CD44 (rs8193) displayed a low but significant correlation between
our estimates of allelic imbalance obtained from the Illumina assay
and those using quantitative sequencing (p,10
24,r
2= 0.4075),
even though the average level of allelic imbalance was below our
significance cut-off on the Illumina platform. Allelic imbalance at
CD44 has been previously reported [30] and it is likely that the
signal observed at that gene is real but corresponds to a low level of
differential expression. Two genes (ABL2, XRCC1) showed
significant allelic imbalance in the Illumina ASE assay (with a
mean allelic ratio of, respectively, 70:30 and 65:35) but were not
validated by quantitative sequencing. Manual inspection of the
Illumina results for these genes revealed that the allelic expression
ratios were estimated using a small number of homozygotes for the
minor allele (respectively, 1 and 2 individuals) which led to an
incorrect estimation of the expected dye ratio for heterozygotes
and to a general over-estimation of allelic imbalance. For further
analyses, we manually curated the list of all genes with significant
differential allelic expression to remove potential false positives due
to low number of homozygous individuals.
Reproducibility of Allelic Imbalance Measured in Cell
Lines
Our study uses lymphoblastoid cell lines (LCLs) and it remains
controversial whether culture conditions could artefactually
generate differential allelic expression. We therefore tested
whether allelic imbalance is influenced by harvesting the cells
after different numbers of passages. This allowed us to control the
effect of changes in the culture environment including pH,
nutrient concentration and cell density at the time of harvest. We
compared our estimation of allelic imbalance for three genes with
significant population-average allelic imbalance in 47 individuals
Figure 6. Cross-validation by quantitative sequencing. The correlations between the estimates of allelic imbalance using Illumina ASE assay
(x-axis) and quantitative sequencing (y-axis) are shown for all individuals heterozygous for IGF1 (A) and GLI1 (B). IGF1 displays significant population-
average allelic imbalance (with a mean allelic ratio of 60:40) and the estimates from quantitative sequencing are very similar with those from Illumina.
In contrast, GLI1 did not show significant allelic imbalance (the population-average ratio is close to 55:45 below the significance threshold of 60:40)
and the estimates from quantitative sequencing of the same individuals are not correlated with those of Illumina (as expected if they only result from
stochastic noise).
doi:10.1371/journal.pgen.1000006.g006
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nd,4
th and 6
th
successive passages (respectively, ‘‘growths’’ 1, 2 and 3). The
correlations between the allelic imbalance estimations are
displayed in Figure S4 for the comparison of growths 2 and 3.
The estimations of allelic imbalance after different passages were
very similar to each other (r
2.0.9), supporting the idea that
differential allelic expression is little influenced by variations in
culture environment.
Comparison of Differential Allelic Expression with Total
Gene Expression Association
An alternative approach to identifying cis-regulatory polymor-
phisms is to test for statistical association in a population between
totalgeneexpressionmeasurementsandthegenotypesatmarkersin
or surrounding the transcript. Interestingly, one of the genes
showing the most marked difference in allele expression in our
analysis is one of the 14 genes identified by Cheung and colleagues
in a previous genome-wide study [17]. One comprehensive analysis
was recently conducted for 512 RefSeq genes in ENCODE regions
and chromosome 21 using LCLs from 60 unrelated individuals
genotyped by the HapMap project [19]. In order to compare the
respective strengths and weaknesses of total gene expression
mapping and differential allelic expression, we designed a second
panelthat includesSNPsinthe same genomicregionstoanalyze the
same individual LCLs (Figure 1 and Table S1 for details). Using the
information from the HapMap phase I (release 16) to select
common exonic SNPs, we were able to include 228 and 124 genes
from, respectively, ENCODE regions and chromosome 21, while
Stranger and colleagues selected 321 and 191 genes (after screening
for genes with high variance in their expression among individuals,
see Materials and Methods for details). From the regions analyzed
by Stranger and al., two-hundreds and ninety SNPs (in 170 genes)
showed an expression level significantly higher than the background
in three or more heterozygous individuals and were further
investigated. Forty-nine out of 170 genes show significant level of
differential allelic expression including 6 out of the 21 genes
identified by Stranger and colleagues and present in our panel.
Additionally, TTC3 which shows significant association between
total gene expression and genotypes in the study by Stranger et al.
shows patterns of allelic expression consistent with differential allelic
expression (including a very high correlation between the extent of
differential allelic expression estimated using different SNPs) on the
Illumina ASE assay, even though it did not pass the significance cut-
off. Overall in this second panel, 497 SNPs in 317 genes were
expressed in three or more heterozygous individuals (out of 1536
SNPs in 674 genes) and 78 SNPs in 65 genes showed a significant
level of differential allelic expression (Figure 1).
Intronic SNPs Can Be Used To Assess Differential Allelic
To test whether intronic SNPs could be used instead of exonic
SNP, we included for each gene on the second panel one intronic
SNP. In general, intronic SNPs were less successfully analyzed and
passed our expression threshold only for genes highly expressed in
LCLs (Figure S5). This finding is consistent with previous
observations [30] and the low proportion of unspliced mRNA
(heteronuclear RNA) in cells relative to spliced transcripts. If the
intronic SNP of a gene was detected in the RNA extract, it
typically yields estimates of differential allelic expression very
similar with those obtained using exonic SNPs.
Differential Allelic Expression in the Human Genome
Overall, 177 out of 1,009 expressed SNPs (in 140 out of 643
genes expressed, 22%) display population-average ratios of allelic
expression larger than 40:60 or an higher than expected variance
in allelic expression among heterozygous individuals and are thus
unlikely to result solely from stochastic variation in the experiment
(Figure S6). Table 1 shows the 133 SNPs (100 genes) with
significant allelic imbalance after manual curation to remove
possible false positives due to a low number of individual
homozygous for the minor allele (this list is likely over-conservative
and the complete data is presented in Table S2).
Many of the genes with the highest extent of allelic imbalance in
LCLs are located on the X-chromosome. While it is known that
one allele at most X-linked genes is silenced in females by
inactivation of one entire chromosome [34,35], we would expect
that a polyclonal cell population (in which half of the cells
inactivate one X chromosome and the other 50% inactivate the
alternate X chromosome) would give a similar level of expression
for both alleles. However, all X-linked genes on our two SNP
panels (22 SNPs in 12 genes) were among the top 5% of genes with
most dramatic allelic imbalance patterns. The extent of allelic
imbalance at a given gene varies among individual LCLs but
interestingly, the patterns of allelic imbalance are very consistent
across genes for a given individual (Figure S7). Additionally, the
inheritance of the expressed allele (determined, when possible,
using the pedigree information for the two families included in this
study) appeared random. It has been previously proposed that the
extent of clonality of a cell line could explain the patterns of allelic
imbalance at genes with random mono-allelic expression [30]:
clonal cells will all have the same X chromosome inactivated and
thus display very high ratios of allelic imbalance. In contrast, cell-
lines composed of a polyclonal population of lymphoblasts will
have one or the other of their X chromosomes inactivated in
different cells and thus an apparent expression of both alleles (i.e.,
a low extent of differential allelic expression). Our observations at
X-linked genes are consistent with this hypothesis and the biased
clonality of these LCLs, which were created over 20 years ago and
passaged numerous times (see also [30]).
The two autosomal genes displaying the most dramatic allelic
imbalance patterns have previously been shown to be imprinted in
humans: PEG10 [36] and SNRPN [37]. In addition, KCNQ1,
MEST and ZNF215 which are imprinted in humans [38–40] also
show significant differences in allelic expression (Table 1). The
mode of inheritance of the expressed allele also corresponds, in
each case, to what has been described for the expression of these
genes: for PEG10 and SNRPN, heterozygous individuals express
the paternally-inherited allele (i.e. maternally imprinted) while for
KCNQ1 the maternally-inherited allele is expressed. Our limited
pedigree information is not conclusive for MEST and ZNF215.
The only other known imprinted gene analyzable in our panel,
PLAGL1 [41,42] did not pass the significance threshold (i.e. an
allelic ratio greater than 60:40) but shows a population average
allelic imbalance larger than 55:45 and a high correlation between
the two SNPs analyzable in the panel (rs2076684 and rs9373409);
therefore it likely represents a significant difference in allelic
expression.
The 83 remaining genes (103 SNPs) with significant population-
average allelic imbalance included several genes for which allelic
imbalance had been shown in previous studies (e.g. IL1A or IGF1
described in [30]). For some genes (e.g., CHI3L2), one allele/
haplotype is clearly expressed more than the other in heterozy-
gotes and the inheritance pattern in families supports a genetic
cause for allelic imbalance. For other genes, neither the direction
of allelic imbalance nor the pedigree analysis allowed us to easily
differentiate the genetic/epigenetic cause of the differential allelic
expression (Table 1). For 56 genes with significant differences in
allelic expression we tested whether differential allelic expression
Cis-Acting Regulation in Humans
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rs Gene Panel Chr
#
Hets
Variance &
Mean Average AI
rs2292305 THBS1 Cancer 15 13 Mean shifted NA
rs2288539 NR2F6 Cancer 19 18 Mean shifted NA
rs2459216 OAT Cancer 10 6 High variance NA
rs3750105 PEG10 Cancer 7 8 High variance NA
rs3745410 LILRB3 Encode 19 5 High variance NA
rs2839500 TMPRSS3 Encode 21 13 High variance NA
rs546782 FGF9 Cancer 13 10 High variance NA
rs17756426 DDX43 Encode 6 6 High variance NA
rs1893963 DSC2 Cancer 18 14 High variance NA
rs9978281 C21orf7 Encode 21 12 High variance NA
rs2834601 CLIC6 Encode 21 8 High variance NA
rs2070807 DNASE1L1 Encode X 5 High variance NA
rs705 SNRPN Cancer 15 42 High variance 95:05
rs7810469 PEG10 Cancer 7 12 High variance 95:05
rs13073 PEG10 Cancer 7 35 High variance 95:05
rs2240176 FLJ35801 Encode 22 18 95:05
rs311683 DDX43 Encode 6 15 High variance 90:10
rs5956583 BIRC4 Cancer X 21 High variance 90:10
rs1056831 CHI3L2 Cancer 1 39 90:10
rs1050757 G6PD Encode X 6 Mean shifted 90:10
rs1474593 BIRC4 Encode X 19 High variance 90:10
rs8371 BIRC4 Cancer X 20 High variance 85:15
rs1800291 F8 Encode X 6 85:15
rs2734647 MECP2 Cancer X 12 High variance 85:15
rs1057403 BTK Cancer X 4 85:15
rs1059701 IRAK1 Cancer X 14 High variance 85:15
rs700 BTK Cancer X 22 High variance 85:15
rs9018 FHL1 Cancer X 4 85:15
rs2734647 MECP2 Encode X 10 85:15
rs3813455 GAB3 Encode X 10 High variance 85:15
rs5945431 PLXNA3 Encode X 9 High variance 85:15
rs5958343 BIRC4 Cancer X 26 High variance 85:15
rs5987266 PLXNA3 Encode X 10 High variance 85:15
rs311686 DDX43 Encode 6 17 High variance 85:15
rs9856 BIRC4 Cancer X 24 High variance 85:15
rs6151429 ARSA Encode 22 24 85:15
rs17330644 BIRC4 Encode X 15 High variance 80:20
rs1050705 F8 Encode X 12 High variance 80:20
rs11887 VBP1 Cancer X 12 High variance 80:20
rs12877 DNASE1L1 Cancer X 4 80:20
rs10798 KCNQ1 Cancer 11 31 High variance 75:25
rs6571303 CXorf12 Encode X 8 75:25
rs9394782 NCR2 Encode 6 15 75:25
rs183436 ABCG1 Encode 21 36 75:25
rs6691569 FCRL3 Encode 1 12 75:25
rs17561 IL1A Cancer 2 21 High variance 75:25
rs2278699 ZAP70 Cancer 2 3 75:25
rs8535 CHI3L2 Cancer 1 38 High variance 75:25
rs1056825 CHI3L2 Cancer 1 38 High variance 75:25
rs1304037 IL1A Cancer 2 26 High variance 75:25
Table 1. cont.
rs Gene Panel Chr
#
Hets
Variance &
Mean Average AI
rs1571858 GSTM3 Encode 1 17 High variance 75:25
rs3817405 PLXDC2 Cancer 10 12 High variance 75:25
rs10863 MEST Cancer 7 29 High variance 70:30
rs10336 CXCL9 Cancer 4 11 High variance 70:30
rs5351 EDNRB Cancer 13 22 High variance 70:30
rs1022477 RIBC2 Encode 22 26 70:30
rs6007897 CELSR1 Encode 22 10 High variance 70:30
rs11264793 FCRL3 Encode 1 24 70:30
rs4445669 IGSF4 Cancer 11 40 High variance 70:30
rs4767884 PXN Cancer 12 26 70:30
rs1041985 CDH2 Encode 18 38 70:30
rs140519 KLHDC7B Encode 22 30 70:30
rs17197 PTGER2 Encode 14 10 70:30
rs1803965 MGMT Cancer 10 5 70:30
rs2837029 C21orf13 Encode 21 15 Mean shifted 70:30
rs724558 SERPINB10 Encode 18 23 70:30
rs6007594 C22orf8 Encode 22 28 70:30
rs7561 LAMB1 Cancer 7 21 High variance 70:30
rs165602 NEFH Encode 22 6 70:30
rs10593 ITGB1BP1 Cancer 2 23 High variance 65:35
rs1042531 PCK1 Encode 20 9 65:35
rs1025689 IL17RB Cancer 3 29 65:35
rs225334 TFF2 Encode 21 17 65:35
rs17207369 LILRP2 Encode 19 18 65:35
rs3856806 PPARG Encode 3 5 High variance 65:35
rs300239 ENC1 Cancer 5 27 65:35
rs677688 IMPACT Cancer 18 7 65:35
rs6104 SERPINB2 Cancer 18 19 High variance 65:35
rs8097425 SERPINB10 Encode 18 24 65:35
rs1071676 IL1B Cancer 2 29 High variance 65:35
rs9612234 GNAZ Encode 22 16 65:35
rs2024233 WNT2 Encode 7 24 High variance 65:35
rs7927012 TRIM6 Encode 11 30 65:35
rs2024233 WNT2 Cancer 7 15 High variance 65:35
rs162549 CYP1B1 Cancer 2 22 High variance 65:35
rs2075760 PLSCR3 Cancer 17 19 65:35
rs2832236 C21orf7 Encode 21 40 High variance 65:35
rs15017 MOXD1 Encode 6 6 High variance 60:40
rs1053474 IMPACT Cancer 18 31 60:40
rs7120209 TRIM6 Encode 11 13 60:40
rs958 MAPK10 Cancer 4 28 60:40
rs7914 MCAM Cancer 11 31 High variance 60:40
rs12593359 RAD51 Cancer 15 44 60:40
rs1368439 IL12B Encode 5 23 60:40
rs1103229 PPIL2 Encode 22 26 60:40
rs2839600 NDUFV3 Encode 21 17 60:40
rs3734744 MOXD1 Encode 6 11 60:40
rs8807 HLA Cancer 6 15 60:40
rs743616 ARSA Encode 22 37 60:40
rs6214 IGF1 Cancer 12 31 High variance 60:40
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the gene genotyped by the HapMap project (see Materials &
Methods for details). The results of these tests for SERPINB10 and
ABCG1 are shown on Figure 7 and the strongest nominal
association for each gene is displayed on Table 2. Twenty-three
genes still display statistical significant associations after Bonferroni
correction for multiple testing (highlighted in green on Table 2)
showing a clear enrichment relative to the 2–3 associations
expected by chance. Our power to detect a significant association
between a HapMap SNP and the under-/over-expressing
chromosome in this setting is low due to our reduced sample
size (only the heterozygous individuals are taken into account in
this analysis) and the number of regulatory haplotypes identified is
thus likely underestimated. Additionally, many SNPs are tested for
each gene and it is thus possible that some of the regulatory
haplotypes result from spurious associations (i.e. they are false
positives). One argument against a very high rate of false positive
in our analysis is that imprinted genes such as MEST or PEG10 do
not show any signal of association (Figure S8) consistent with the
fact that the cis-regulatory mechanism at these genes is not
encoded in the DNA sequence. To further investigate the validity
of our association, we attempted to independently confirm these
regulatory haplotypes by testing for the statistical association
between one SNP in the regulatory haplotype and gene expression
level. We used gene expression measurements performed at the
Wellcome Trust Sanger Institute (kindly provided by M. Dermitza-
kis) on the same individual cell lines assayed by Illumina gene
expression arrays. For each gene, we tested whether the homozy-
gotes for the regulatory haplotype associated with low allelic
expression in heterozygotes show a significantly lower gene
expression level than the homozygous individuals for the regulatory
haplotype associated with high allelic expression. We also performed
locus-specific RT-PCR and quantified the level of gene expression
using SYBR-Green for eleven genes for which differential allelic
expression was significantly associated with allelic expression but for
which expression data were not available (2 genes) or genes with
strong association with a regulatory haplotype but that were not
validated using the Sanger dataset (9 genes). Overall, out of the 47
genes with a significant association between a SNP (or several,
defining the regulatory haplotype) and differential allelic expression
at the nominal cut-off, 10 were confirmed using gene expression
measurements while 5 other genes showed a trend but did not reach
statistical significance (Table 2).
Discussion
Biology, Not Experimental Noise, Is Responsible for
Differential Allelic Expression
We analyzed differences in relative allelic expression (or allelic
imbalance) at 1,380 human genes using 2,968 SNPs and more
than 80 lymphoblastoid cell lines from individuals with European
ancestry. Using quantitative sequencing we validated our results
for a subset of genes and showed that the experimental variability
in both settings is low and that the Illumina ASE assay and
quantitative sequencing of RT-PCR products yield reproducible
estimates of allelic imbalance consistent with each other. Overall,
the experimental noise is much lower than the difference in
relative allelic expression observed at many loci and therefore
cannot be responsible for it. Additionally, the high concordance of
the results obtained using different SNPs in the same transcript
supports our findings that allelic imbalance, as we estimated it, is
not an experimental artefact but reflects inherent biological
differences in the relative expression of both alleles in heterozygous
individuals. We also showed that lymphoblastoid cell lines, despite
being simplified biological materials, are suitable resources to
investigate mechanisms of gene regulation. Here, we demonstrated
that our estimation of allelic imbalance is little affected by growth
conditions and that LCLs harvested from different passages yield
very similar results. Finally, the results efficiently recapitulate the
consequences of the epigenetic mechanisms established in the
individuals from which the cells have been derived (see also [43]).
We are therefore confident that, overall, the patterns of allelic
imbalance we observed are neither experimental artifacts, nor
specific to the material studied, but represent a common biological
phenomenon affecting human gene expression.
Table 1. cont.
rs Gene Panel Chr
#
Hets
Variance &
Mean Average AI
rs2822445 RBM11 Encode 21 38 60:40
rs4947963 EGFR Encode 7 19 60:40
rs5275 PTGS2 Cancer 1 41 60:40
rs2257505 MGC33648 Encode 5 29 60:40
rs1029365 FLJ21062 Encode 7 30 60:40
rs2839536 TSGA2 Encode 21 19 60:40
rs6518322 LOC284837 Encode 21 29 60:40
rs2258119 C21orf91 Encode 21 25 60:40
rs2229730 CSK Cancer 15 4 60:40
rs2206593 PTGS2 Cancer 1 10 High variance 60:40
rs2829877 JAM2 Encode 21 17 60:40
rs1053395 TUBB4 Cancer 19 32 60:40
rs1044104 BMP6 Cancer 6 22 60:40
rs1801719 F2R Cancer 5 31 60:40
rs235768 BMP2 Cancer 20 7 High variance 60:40
rs2239730 ZNF215 Cancer 11 41 60:40
rs2270121 GAS7 Cancer 17 38 60:40
rs963075 SERPINB10 Encode 18 32 High variance 60:40
rs4820268 TMPRSS6 Encode 22 38 60:40
rs4798 ITGB1BP1 Cancer 2 34 60:40
rs9782 ASCL1 Cancer 12 28 60:40
rs180817 BCR Cancer 22 15 60:40
rs406271 TFRC Cancer 3 33 60:40
rs1476217 FGF2 Cancer 4 43 High variance 60:40
rs2239731 ZNF215 Cancer 11 44 60:40
rs10916 CYP1B1 Cancer 2 13 High variance 60:40
rs2230033 KCNJ15 Encode 21 33 60:40
rs3088440 CDKN2A Cancer 9 31 60:40
rs2855658 CYP1B1 Cancer 2 37 High variance 55:45
rs14983 MMP7 Cancer 11 22 High variance 55:45
rs3747676 FGF2 Cancer 4 42 High variance 55:45
rs10502001 MMP7 Cancer 11 19 High variance 55:45
rs2066575 DLEU1 Cancer 13 27 High variance 55:45
#Hets: number of heterozygous individuals which express the transcript.
Variance & Mean: indicates whether the analyses of variance/mean allelic
expression detected significant deviation of the expression of both alleles (see
Materials and Methods for details).
Average AI: population-average difference in allelic expression using all
individuals heterozygous at this position (rounded down). These values
correspond to values reported on the y-axis on Figure 4 and Figure S6.
doi:10.1371/journal.pgen.1000006.t001
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Epigenetic Mechanisms of Gene Regulation
We showed that LCLs derived from female individuals still
harbor the consequences of X-inactivation at all X-linked genes
investigated, with one allele being transcriptionally silenced [34].
The extent of allelic imbalance detected at X-linked genes can
vary among LCLs due to the various degrees of clonality of these
cells but clonal LCLs consistently show complete silencing of one
allele at all X-linked genes investigated (Figure S7). In addition,
imprinting, established in the germ lines of the parents of the
individuals from which the cells are derived [44], is also
maintained in LCLs. In our experiments, PEG10, SNPRN,
MEST and KCNQ1 show reduced or absent expression of one
Figure 7. Association mapping of allelic imbalance to regulatory haplotypes for SERPINB10 (A) and ABCG1 (B). The green track shows
the –log(p.value) for the association of the alleles for each SNP with the over-/under-expressing chromosome (i.e. the higher the bar, the strongest
the association). The linkage disequilibrium pattern for the CEPH individuals genotyped by the HapMap project is displayed below (using r
2).
doi:10.1371/journal.pgen.1000006.g007
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Gene Chr # Hets Association Sanger RT-PCR Mapped to
ABCG1 21 18 2.20E-10 6.81E-01 5.78E-01 Intron
ARSA 22 17 2.26E-05 NA Gene
ASCL1 12 13 1.69E-02 1.37E-02
BCR 22 6 6.06E-02 9.83E-01
BMP6 6 5 4.76E-02 8.62E-01
C21orf13 21 9 4.11E-05 No data 3.78E-02 Gene-59
C21orf7 21 12 3.71E-01 7.06E-01
C21orf91 21 17 1.54E-08 8.47E-04 Gene
C22orf8 22 8 1.55E-04 No data Gene
CDH2 18 22 5.32E-05 7.00E-01 Gene
CXCL9 4 7 4.66E-03 3.43E-01 Whole Region
CYP1B1 2 17 2.11E-06 1.43E-02 Gene-59
DDX43 6 9 3.47E-01 5.56E-01
EDNRB 13 14 7.03E-03 6.17E-01 Whole Region
EGFR 7 6 4.55E-01 6.21E-01
F2R 5 10 1.08E-05 7.32E-01 9.65E-02 39UTR
FCRL3 1 14 6.88E-05 No data 8.04E-03 Gene-39
FGF2 4 22 6.00E-03 7.63E-01 Gene-39
FLJ35801 22 13 4.72E-02 1.23E-01
GAS7 17 12 7.40E-07 2.96E-01 1.45E-01 39UTR
GNAZ 22 5 7.94E-03 6.42E-01 1.16E-01 Gene-39
IGF1 12 13 2.38E-01 9.17E-01
IGSF4 11 15 1.70E-03 2.91E-01 2.59E-01 Gene-39
IL12B 5 13 1.92E-07 4.51E-02 Whole Region
IL17RB 3 14 5.98E-06 6.81E-01 7.33E-01 59
IL1A 2 9 1.49E-01 8.74E-01
IMPACT 18 11 7.52E-03 6.63E-01 59distal ?
ITGB1BP1 2 18 1.58E-03 No data Gene
JAM2 21 9 2.26E-03 NA 59 ?
KCNJ15 21 13 1.69E-02 3.25E-01 Gene
KCNQ1 11 21 2.07E-02 1.59E-01
KLHDC7B 22 21 3.72E-12 No data Gene-39
LILRP2 19 10 2.30E-02 No data
LOC284837 21 16 3.73E-02 No data
MAPK10 4 11 2.84E-06 5.25E-01 Gene
MCAM 11 12 6.44E-04 5.21E-01 Gene/39
MEST 7 9 1.53E-01 5.50E-01
MGC33648 5 21 4.40E-06 3.59E-05 59
MMP7 11 8 4.66E-03 7.46E-01
MOXD1 6 8 6.99E-03 1.12E-01 59
NDUFV3 21 11 2.84E-06 3.73E-05 Gene-39
PEG10 7 22 4.59E-02 NA
PLSCR3 17 10 1.98E-02 2.22E-01
PLXDC2 10 8 7.69E-02 3.40E-02
PTGS2 1 5 2.06E-01 NA
PXN 12 14 4.23E-04 9.24E-01 Gene-39
RBM11 21 10 1.08E-05 4.59E-01 1.71E-01 39
RIBC2 22 12 7.40E-07 No data Gene
SERPINB10 18 22 1.84E-05 5.98E-11 59
SERPINB2 18 10 1.19E-04 2.98E-01 Gene-59
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corresponds to the imprinting mechanism described in the
literature (i.e. PEG10 and SNPRN are maternally imprinted,
KCNQ1 is paternally imprinted). We thus observe extensive
differential allelic expression (i.e. allelic ratio larger than 70:30) for
all genes whose expression is known to be epigenetically regulated.
This clearly shows that analysis of differential allelic expression is a
suitable method for identifying the consequences of epigenetic
mechanisms of gene regulation. The Illumina ASE assay would
thus provide an efficient method to screen tumor tissues and
identify patterns of differential allelic expression resulting from
aberrant methylation or loss of imprinting that are known to be
involved in the etiology of cancers [45–47].
Interestingly, IMPACT which shows significant extent of allelic
imbalance at two SNPs (rs677688 and rs1053474) in our study, is
known to be imprinted in mice [48] but not in humans [49]. The
mode of inheritance of the over-expressed alleles could not be
determined using the two families available in our study (i.e. the
parents were always homozygous for the same allele). The attempt
to map differential expression to a regulatory haplotype was not
successful and is consistent with an epigenetic mechanism of gene
regulation. More investigations are required to determine whether
the pattern of allelic imbalance observed for IMPACT results from
incomplete silencing of one allele following imprinting in the
parental germ-lines or whether it results from random mono-allelic
expression or another mechanism of gene expression regulation.
Regulatory Polymorphisms Determine Allelic Expression
for Some Human Genes
Ouranalysisof643genesexpressedinLCLsshowsthat,foralarge
proportion of them (,20%), the two alleles are differentially
expressed in most heterozygous individuals. For 18 genes, differential
expression resulted from a known epigenetic silencing of one of the
two alleles, either through X-inactivation in females or imprinting.
The mechanisms leading to allele-specific expression at all other
genes could be driven by a polymorphism affecting the cis-acting
regulation (e.g. a SNP in a transcription factor or a miRNA biding
site) or simply result from random silencing of one of the two alleles.
We tested 56 genes for association of differential allelic expression
patterns observed with a cis-acting regulatory polymorphism using
genotypes generated by the HapMap project (see Materials and
Methods for details). For 23 of these genes we identified a region
statistically associated with differences in allele expression that could
indicate the existence of a regulatory haplotype (i.e., a region of one
chromosome likely containing the polymorphism(s) causing the
differential cis-regulation). These regions are often tens of kb long,
consistent with previous descriptions of the linkage disequilibrium
patterns in humans [50]. Although this approach does not identify
the actual polymorphism(s) responsible for the differential cis-
regulation, examination of these regulatory haplotypes provides
some valuable insights on the mechanisms leading to differential
expression and can guide future investigations. For example, the
regulatory haplotype for GAS7 is almost exclusively restricted to the
39UTR of the gene and may indicate that the patterns of allelic
imbalance observed are due to differential mRNA processing,
stability or the presence of a 39 enhancer. In contrast, the regulatory
haplotype identified for MGC33648 is located in the 59 region and
doesnot seemto overlap withthe gene itself.This might be indicative
of alternative promoter usage or differential transcription efficiency
(e.g. due to differential transcription factor binding site affinity).
Allelic Imbalance Is Complementary of Total Gene
Expression Association
Several recent studies have used large-scale associations
between gene expression and extensive genotype information to
investigate gene regulation in humans, some of them using cell
lines included in our study. In particular, Stranger and colleagues
analyzed 630 genes located in ENCODE regions, on chromosome
21 and in one portion of chromosome 20. They found evidence of
cis-acting regulation for 63 genes [19]. 2005). We were able to
analyze 21 of these genes in our experiment. Six of them also
showed evidence of cis-acting regulation (e.g. SERPINB10 or
TSGA2) in our study while a seventh gene (TTC3) showed
patterns consistent with differential allelic expression but did not
reach our significance threshold. The remaining 14 genes did not
show evidence of differential allelic expression in our analysis.
Alternatively, we identified 10 new genes located in ENCODE
region or chromosome 21 that showed significant level of
differential allelic expression but were not detected in the Stranger
study. Several non-exclusive reasons could explain the discrepan-
cies between the results of the two approaches. First, it is worth
noting that, even if the same individuals are analyzed by allelic-
specific expression and gene expression association, the power to
detect cis-acting effect differs depending on the allele frequency of
the marker used: in gene expression association analysis all
individuals are analyzed but the power in the regression analysis
Table 2. cont.
Gene Chr # Hets Association Sanger RT-PCR Mapped to
SNRPN 15 27 3.94E-02 3.78E-01
TMPRSS6 22 12 7.40E-07 8.42E-01 39UTR
TRIM6 11 8 2.56E-02 9.84E-01
TSGA2 21 8 1.55E-04 9.81E-01 Gene
WNT2 7 9 9.05E-03 3.60E-01 6.45E-01 59 Gene
ZNF215 11 20 3.73E-02 1.45E-03 1.82E-02 Gene-59
#Hets: number of heterozygous individuals for the gene considered among the HapMap individuals analyzed.
Association: lowest nominal p-value obtained by Fischer exact test of the association of the alleles of all SNPs with over-/under-expressing chromosomes. Associations
remaining significant after Bonferroni correction for multiple testing are highlighted in green.
Sanger: p-value obtained in the linear regression of the Sanger gene expression measurements with the alleles of the SNP most strongly associated with allelic
expression.
RT-PCR: p-value obtained in the linear regression of the locus-specific RT-PCR gene expression measurements with the alleles of the SNP most strongly associated with
allelic expression.
Mapped to: broad localization of the regulatory haplotype with regards to the gene with significant difference in allele expression.
doi:10.1371/journal.pgen.1000006.t002
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encoded in the linear regression as 0, 1 and 2) while in allelic
expression analysis only the individuals heterozygotes at the
marker considered are analyzed. This can become particularly
problematic to study differential allelic expression at some genes
since it requires a relatively common exonic SNP to detect allelic
imbalance. In this context, it is worth noting that intronic SNPs
can successfully be used for genes that are highly expressed (see
also [30]). Second, associations of gene expression to genotypes
depends greatly on the linkage disequilibrium (LD) patterns and
requires extensive genotype information from all the individuals in
order to include one marker in LD with the regulatory
polymorphism. Allelic expression, on the other hand, directly
investigate cis effect directly at the gene level and thus only requires
physical link between the gene and the regulatory polymorphism
affecting it (i.e. they need to be on the same chromosome). Finally,
the differences between allelic expression and gene expression
mapping might indicate that some genes are also regulated by
trans-acting mechanisms that differ among individuals: differential
allelic expression is influenced only by cis-acting mechanisms of
gene regulation while gene expression is influenced by cis- and
trans-acting gene regulation. It is thus not unlikely that individual
differences in trans-acting regulation swamp the signal from cis-
acting polymorphisms. In this context, it is noteworthy that total
gene expression mapping has been much more successful in mice
and yeast forwhichthe genetic heterogeneityis muchlowerand can
be controlled (reviewed in [9,10,51]). In humans, or in any other
outbred population, genetic heterogeneity greatly limits the
identification of cis-acting mechanisms using gene expression data
while measurements of differential allelic expression are unaffected.
We showed here that allelic expression assays are complemen-
tary from gene expression mapping and that the Illumina ASE
assay overcomes two of the major limitations and criticisms of the
former methodologies used to assess differential allelic expression:
it allows a robust and high-throughput estimation of allelic
imbalance: it is now possible to reliably screen hundreds of RNAs
for several hundreds of genes in a couple of days. Additionally,
when several SNPs can be used to assess differential allelic
expression, the assay becomes very robust since each marker
provides an independent estimation and one can test the
correlation among estimates obtained at different positions. It is
worth noting here that since this assay relies on the comparison of
allelic ratio in DNA and RNA of each individual, it internally
controls for the existence of polymorphisms in the primer sites or
copy number variation encompassing the gene studied (that will
affect equally DNA and RNA). Likely, the greatest advantage of
the analysis of differential allelic expression over total gene
expression is its flexibility. To identify differential regulation of
gene expression using total gene expression, one needs extensive
genotype information to test whether, at any polymorphic
position, the gene expression differences among individuals
segregate according to their genotype. This precludes a quick
assessment of the expression of one locus in one cohort of
particular interest or using a specific tissue. In contrary, differential
allelic expression offers the advantage that any one gene can be
quickly assessed in any cohort or tissue by simply comparing the
expression of the two alleles in each individual (the amount of
genetic information recently made available by the HapMap
project allows a quick and easy selection of markers likely to be
polymorphic for a given gene). The determination of regulatory
haplotypes would still require extensive information concerning
surrounding polymorphisms but the initial screening to determine
whether one transcript is differentially cis-regulated can be done
very efficiently with a handful of markers.
Conclusion
We showed that differential allelic expression is a robust
approach to identify cis-acting mechanism of gene regulation. It
complements gene expression association studies and offers
additional perspectives, notably on epigenetic mechanisms of gene
regulation. It could thus be particularly interesting to apply this
assay to tumors to detect mis-regulated genes due to aberrant
methylation patterns or loss of imprinting. In addition, our
approach is applicable to any new cohort or tissue since it is self-
sufficient to identify differential cis-regulation and does not require
additional genotyping. It can be easily used to follow-up interesting
non-coding regions associated to a particular disease and test if
they are involved in the etiology of the disease through some
regulatory effects on neighboring genes.
Materials and Methods
Sample Preparation
83 lymphoblastoid cell lines (LCL) derived from blood samples
from the CEPH collection were selected for this project. They
included 60 unrelated individuals obtained from Utah residents
with ancestry from western and northern Europe for which DNA
was genotyped for millions of SNPs covering the entire genome by
the International HapMap Project. Additionally, 21 LCLs from
CEPH pedigrees 1420 and 1444 were included to provide
complete information on two three-generation CEPH families.
Cells were grown at 37uC and 5% CO2 in RPMI 1640 medium
(Invitrogen, Burlington, Canada) supplemented with 15% heat-
inactivated fetal bovine serum (Sigma-Aldricht, Oakville, Canda),
2 mM L-glutamine (Invitrogen, Burlington, Canada) and penicil-
lin/streptomycin (Invitrogen, Burlington, Canada). The cell
growth was monitored with a hemocytometer and the cells were
harvested when the density reached 0.8–1.1610
6 cells/mL. Cells
were then resuspended and lysed in TRIzol reagent (Invitrogen,
Burlington, Canada). For all LCLs, three successive growths were
performed (corresponding to the 2
nd,4
th and 6
th passages) after
thawing frozen cell aliquots.
Illumina Allele-Specific Expression (ASE) Assay
We estimated allelic imbalance at 1,380 genes (two panels of
,1,500 SNPs, Figure 1) using the Illumina ASE assay (Figure 2).
The experiment is similar to the one used for large-scale SNP
genotyping [52] and gene expression profiling [53] except that
DNA and RNA are independently assessed and compared to each
other. RNA was first converted into biotinylated cDNA [53] while
DNA was treated according to the usual GoldenGate assay
protocol [52]. Biotinylated DNA (derived from genomic DNA or
mRNA) was immobilized on paramagnetic beads and pooled
SNP-specific oligonucleotides were annealed on the DNA.
Hybridized oligonucleotides were then extended and ligated to
generate DNA templates, which were amplified using universal
fluorescently-labeled primers. Finally, single-stranded PCR prod-
ucts were hybridized to a Sentrix Array Matrix [52], and the
arrays were imaged using the BeadArray Reader Scanner [54]. 96
samples (DNA or RNA) were analyzed per Sentrix Array for
,1,500 SNPs. All RNA measurements were performed in
duplicates.
Analyses of ASE Results
To estimate the extent of allelic imbalance in heterozygote
individuals at each SNP of the Illumina ASE panel, we developed
algorithms using two different approaches: i) we used information
from individuals of all three genotypes (AA, AB and BB), and/or ii)
we used only the heterozygote individuals.
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a determined background in a given individual. To do so, we
made use of the fact that the genotypes were known (from the
DNA analysis) and developed a locus-specific expression back-
ground cut-off: homozygote individuals (i.e. AA or BB) can only
express the corresponding allele, respectively A or B, at the RNA
level (if at all). We thus determined a background fluorescence
level (i.e. corresponding to random noise) for each allele (i.e. A and
B) by measuring the emission in the corresponding dye
(respectively, Cy3 and Cy5) in individuals homozygous for the
other allele (respectively BB and AA). This is represented
schematically on Figure S9. To avoid false positive results due to
the inclusion of transcripts not expressed in the cell lines
considered, we used a conservative approach and arbitrarily fixed
the background emission cutoff to the maximum emission of the
absent allele of all homozygotes, plus the mean emission of the
absent allele divided by the number of homozygotes (to weight the
uncertainty in the determination of the ‘‘maximum noise’’ by the
numbers of individuals used to determine it). This procedure
allowed us to independently estimate the background emission of
each allele/dye specifically for each SNP, which is particularly
important because the fluorescence emission can differ drastically
between the dyes and among loci (data not shown). We then
proceeded to the detection call using the background cut-offs:
individuals with genotypes AA were considered to express a given
transcript if the emission was larger than twice the cutoff
background emission of A, individuals with genotypes AB if the
fluorescence was larger than the sum of the background emission
of A and the background emission of B, and individuals with
genotypes BB if the emission is larger than twice the background
emission of B. Since the inclusion in the analyses of transcripts
expressed at low level (or not expressed at all) is very problematic,
we excluded from our analyses all loci for which less than 75% of
the individuals had discordant replicate expression (i.e., one
replicate above expression background, the other under the cut-off
value).
The first method used to determine whether some heterozygote
individuals expressed significantly differently the two alleles is
locus-specific but requires having at least one individual expressed
from each homozygote genotype (AA and BB). In this case, we
determined the median log ratio of the two dyes for each
homozygote clusters at the DNA and RNA level
(e D DAA, e R RAA, e D DBB, e R RBB) as well as the median absolute deviations
(MAD). We used medians and MADs, instead of means and
standard deviations, to down weight the influence of possible
outliers. We then determined a range of ‘‘expected’’ (i.e. non
significant) variation of allelic expression for the heterozygote
individuals. We calculated the equation of the lines joining the
median values plus/minus two MAD of AA and BB and estimated
the range, for the log ratio of the dyes at the RNA level, between
the lines at the value corresponding to the median of DNA in
heterozygote individuals (Figure S10). If the observed log ratio of
dyes for a given heterozygote individual fell outside the expected
range of variation in absence of AI (Figure S8), we scored each
heterozygote individual separately to obtain a quantitative
estimation of allelic imbalance using the ratio:
RAB{ER AB ðÞ ðÞ
e R RAA{ER AB ðÞ
   ,i fR ABwER AB ðÞ
or
RAB{ER AB ðÞ ðÞ
ER AB ðÞ {e R RBB
   ,i fR ABvER AB ðÞ :
This simple estimate indicates both the magnitude of the allelic
imbalance (i.e. the fold difference) and its direction (i.e. which
allele is more expressed than its counterpart).
In order to assess allelic imbalance for SNPs with low minor allele
frequencies (for which homozygote individuals with the minor allele
may not be present in a small sample size panel), we developed a
second method based solely on the heterozygote individuals. If a
given transcript is affected by allelic imbalance we expect that either
the variance of the log ratio of dyes for heterozygote RNAs to be
greatly increased relative to the variance of homozygote RNAs, or, if
one allele is systematically more expressed than the other, the mean
value of these log ratios to be drastically shifted from its expected
intermediate position (between the mean for AA and the mean for
BB homozygote RNAs). For all SNPs with at least five individuals
with the same genotype expressed, we estimated the standard
deviation of the log ratio of dyes for DNA and RNA. The
distribution of the log ratio of the standard deviations (i.e. log sDNA/
sRNA) over all loci for heterozygous individuals differed from those
observed using homozygous individuals and did not seem to fit a
normal distribution (Figure S11). Based on the assumption that this
distributionmayincludesomelociinallelicimbalance(and thuswith
a higher than expected RNA variance), we fitted a mixture of two
Gaussians on our dataset (i.e., one corresponding to the loci with
allelic imbalance, the second including all other loci) using a
Maximum Expectation algorithm implemented in R (mixdist
package). For our data, the best fit was obtained with a minor
distribution (including ,3% of the loci) corresponding to the most
extremely negative log ratios of variances (i.e., that the RNA
standard deviation was larger than expected). For each locus, we
then used the probability of belonging to the ‘‘higher-than-expected
RNA variance’’ distribution as an indication of allelic imbalance.
Quantitative Sequencing of RT-PCR Products
We assessed the extent of allelic imbalance by quantitative
sequencing following the method described in Ge et al. [33].
Briefly, we isolated RNA using TRIzol reagent following the
manufacturer’s instructions. We assessed RNA quality with an
Agilent 2100 Bioanalyzer (Agilent, Palo Alto, USA) before
synthesizing first strand cDNA using random hexamers (Invitro-
gen, Burlington, Canada) and Superscript II reverse transcriptase
(Invitrogen, Burlington, Canada). For each locus, we designed
locus-specific primers, in the exon/UTR containing the SNP
analyzed, at least 50 bp away from the SNP studied. 5 ng of
genomic DNA and 10 ng of total cDNA were then amplified by
PCR using Hot Start Taq Polymerase (Qiagen, Mississauga,
Canada) with an activation step (95uC for 15 minutes) followed by
40 cycles (95uC for 30 s, 55uC for 30 s and 72uC for 45 s) and a
final extension step (72uC for 6 minutes). PCR products were
purified using Exonuclease I and Shrimp Alkaline Phosphatase
(USB, Cleveland, USA) and sequenced using either one of the
former primers or a nested primer, on an Applied Biosystems
3730xl DNA analyzer. We used PeakPeaker v.2.0 [33] with the
default settings to quantify the relative amount of the two alleles
measured from the chromatogram after peak intensity normaliza-
tion. To estimate the experimental variability of the entire
experimental setup we used a hierarchical strategy for two genes
(cf. Figure S12): for two/three individual cell lines, we extracted
independently RNAs three times and performed, on each extract,
three independent RT-PCRs. All cDNA obtained were then split
into three aliquots, each amplified independently by locus-specific
PCR. These PCR products were finally sequenced each three
times (i.e. three independent sequencing reactions). To estimate
the variability at each experimental stage we calculated the mean
standard variation normalized to the mean using the independent
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levels (PCR, RT-PCR), we averaged the values from the lower
level (e.g., to estimate the variability at the PCR level, we
compared the means of the three sequencing values performed on
each of the three PCRs: [s1,s2,s3] vs [s4,s5,s6] vs [s7,s8,s9]). The
results are presented in Text S1.
Association Mapping of Differential Allelic Expression
We attempted to map allelic imbalance to regulatory haplotypes
for all genes with significant differences in allelic expression that
fulfilled these criteria: i) they are mapped on the build 34 of the
human genome, ii) the SNP used in the Illumina ASE assay has
also been genotyped by the HapMap [55] and iii) there are more
than four HapMap individuals heterozygous at the marker SNP.
For each gene, we retrieved the haplotype information from the
phased chromosomes of each of the 57 HapMap CEPH
individuals for 100,000 bp upstream and downstream of the
SNP used to assess allelic imbalance. When a transcript contains
more than one SNP or if two SNPs used to assess allelic imbalance
at two transcripts are separated by less than 200,000 bp, the
region retrieved spans from the most upstream marker plus
100,000 bp to the most downstream marker minus 100,000 bp.
For each individual LCL, the over expressed and under expressed
haplotype/chromosome were identified and each SNP was tested
for segregation of the alleles in under- and over-expressed
chromosomes using a Fischer’s exact test. Between 47 and 592
SNPs were tested for each gene (mean = 229) and the associations
remaining significant after Bonferroni correction for multiple
testing are shown in green in Table 2.
Validation of Regulatory Haplotypes
Illumina total gene expression data were obtained from the
Wellcome Trust Sanger Institute for the 60 unrelated CEPH
individuals genotyped by the HapMap project and included in our
assay. We also determined the total expression for 10 genes using
Real-Time PCR and SYBR Green labeling on an ABI 7900HT
(Applied Biosystems, Foster City, CA) instrument. 8–10 ng of first
strand cDNA were amplified using 0.32 mM of gene specific
primers and Power SYBR Green PCR master mix (Applied
Biosystems) according to the manufacturer’s instructions. The
amplifications started by 95uC for 10 min followed by 40 cycles at
95uC for 20 s, 58uC for 30 s and 72uC for 45 s. We performed the
Real-Time PCR assays for the 60 individuals LCLs genotyped by
the HapMap projects and analyzed 6 replicates per each sample.
A standard curve was established using a dilution series of total
cDNA of known concentration. The Ct for each replicate was
transformed to a relative concentration using the estimated
standard curve function (SDS 2.1, Applied Biosystems) and
normalized based on 18S rRNA Taqman (Applied Biosystems)
expression data obtained for each sample to account for well to
well variability.
Software
All analysis scripts are available upon request. PeakPicker v.2.0
is available at http://www.genomequebec.mcgill.ca/EST-
HapMap/.
Supporting Information
Text S1 Experimental variability using quantitative sequencing
of RT-PCR products.
Found at: doi:10.1371/journal.pgen.1000006.s001 (0.03 MB
DOC)
Figure S1 Correlation between the estimates of allelic expression
and the proportions of total RNA extract mixed. The graph
displays the p-values of the linear regressions between the allelic
ratios and the proportions of mixed RNA. Mixes homozygous-
homozygous are shown in red, mixes heterozygous-homozygous
are in blue.
Found at: doi:10.1371/journal.pgen.1000006.s002 (1.94 MB TIF)
Figure S2 Estimation of experimental variability in the Illumina
ASE assay. Average difference between duplicates for 411 SNPs
analyzed using the Illumina ASE Cancer Panel. The variability is
shown for each SNP as the fraction of the difference between the
median dye ratio for homozygotes for one allele and the median
dye ratio for homozygotes for other allele (e.g., a variability of 0.1
could artificially generate an allelic ratio of 60:40 in heterozy-
gotes).
Found at: doi:10.1371/journal.pgen.1000006.s003 (1.86 MB TIF)
Figure S3 Assessment of differential allelic expression using
quantitative sequencing of RT-PCR products. First strand cDNA
is synthesized from total RNA extract using random hexamers and
amplified by locus-specific primers surrounding a particular coding
SNP. The allelic ratio is estimated directly from the sequencing trace
file with the software PeakPicker v2.0.
Found at: doi:10.1371/journal.pgen.1000006.s004 (3.26 MB TIF)
Figure S4 Influence of the culture conditions. The figure shows
the correlation between the estimates of allelic imbalance using
quantitative sequencing for cells harvested after 4 (‘‘Harvest 2’’, x-
axis) and 6 (‘‘Harvest 3’’, y-axis) passages. Each blue cross stands
for one heterozygous individual for the gene IGF1 (A), IL1A (B)
and CHI3L2 (C).
Found at: doi:10.1371/journal.pgen.1000006.s005 (2.50 MB TIF)
Figure S5 Exonic vs. intronic SNP. The graph shows the
average number of individuals expressing a detectable transcript
using an exonic SNP or an intronic SNP.
Found at: doi:10.1371/journal.pgen.1000006.s006 (1.95 MB TIF)
Figure S6 Population-average estimates of allelic imbalance at
777 SNPs (both panels combined). See legend of Figure 4.
Found at: doi:10.1371/journal.pgen.1000006.s007 (1.93 MB TIF)
Figure S7 Clonality and X-linked genes. The allelic imbalance
estimates for 11 X-linked SNPs (in 7 genes) are displayed on the y-
axis for every female individual (x-axis) (if the individual is
heterozygous at the position considered).
Found at: doi:10.1371/journal.pgen.1000006.s008 (2.50 MB TIF)
Figure S8 Association mapping of allelic imbalance to regula-
tory haplotypes for MEST (A) and PEG10 (B).
Found at: doi:10.1371/journal.pgen.1000006.s009 (4.54 MB TIF)
Figure S9 Method used for the detection of transcript
expression. See Materials and Methods for details.
Found at: doi:10.1371/journal.pgen.1000006.s010 (1.86 MB TIF)
Figure S10 Individual assessment of differential allelic expres-
sion on the Illumina ASE assay. See Materials and Methods for
details.
Found at: doi:10.1371/journal.pgen.1000006.s011 (1.93 MB TIF)
Figure S11 Variance-based assessment of differential allelic
expression on the Illumina ASE assay. See Materials and Methods
for details.
Found at: doi:10.1371/journal.pgen.1000006.s012 (1.91 MB TIF)
Figure S12 Estimation of experimental variability in quantita-
tive sequencing assay. We performed, for two genes (and five
individuals), triplicates of each experimental step: from one cell
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was then subject to three independent RT-PCRs and each aliquot
was amplified three times by locus-specific PCR. Finally, PCR
products were sequenced three times and allelic imbalance
estimated using PeakPicker v2.0.
Found at: doi:10.1371/journal.pgen.1000006.s013 (1.54 MB TIF)
Table S1 List of the 2,968 SNPs analyzed using the Illumina
ASE assay. Origin. Displays if the gene is located in a ENCODE
region, on chromosome 21 or 22 and whether the genes was
included for its potential involvement in disease etiology. Intron/
exon. SNPs in 39UTR are shown as ‘‘exon’’.
Found at: doi:10.1371/journal.pgen.1000006.s014 (0.09 MB PDF)
Table S2 All SNPs expressed in at least three heterozygous
individuals
Found at: doi:10.1371/journal.pgen.1000006.s015 (0.05 MB PDF)
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